A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
We present guidelines for developing synthetic 'chemical transducers' that can induce communication between naturally unrelated proteins. In addition, detailed protocols are presented for synthesizing and testing a specific 'transducer' that enables a growth factor to activate a detoxifying enzyme and consequently, to regulate the cleavage of an anticancer prodrug.
Signal transduction pathways, which control the response of cells to various environmental signals, are mediated by the function of signaling proteins that interact with each other and activate one other with high specificity. Synthetic agents that mimic the function of these proteins might therefore be used to generate unnatural signal transduction steps and consequently, alter the cell's function. We present guidelines for designing 'chemical transducers' that can induce artificial communication between native proteins. In addition, we present detailed protocols for synthesizing and testing a specific 'transducer', which can induce communication between two unrelated proteins: platelet-derived growth-factor (PDGF) and glutathione-S-transferase (GST). The way by which this unnatural PDGF-GST communication could be used to control the cleavage of an anticancer prodrug is also presented, indicating the potential for using such systems in 'artificial signal transduction therapy'. This work is intended to facilitate developing additional 'transducers' of this class, which may be used to mediate intracellular protein-protein communication and consequently, to induce artificial cell signaling pathways.
Signal transduction pathways play a significant role in virtually every cellular process and allow the cell to rapidly respond to environmental signals.1 These pathways are often triggered by the binding of a signaling molecule to an extracellular receptor, which results in activation of intracellular enzymes. Amplification and propagation of this signal within the cell is mediated by the function of signaling proteins that form a network of protein-protein interactions in which enzymes are reversibly activated with high specificity. Because dysregulation of these networks frequently leads to cancer development, there has been much interest in establishing 'signal transduction therapy of cancer',2 whereby drugs are designed to disrupt malignant signaling pathways. We have recently proposed an alternative approach to signal transduction therapy that relies on the ability of drugs to generate unnatural signal transduction pathways.3 In particular, we believe that by designing synthetic agents that mimic the function of signaling proteins, it would be possible to modulate the cell's function indirectly. For example, these artificial networks may enable protein biomarkers to activate enzymes that cleave prodrugs. Alternatively, these signaling protein mimetics might be able to activate unnatural cell signaling pathways, resulting in therapeutic effects.
To demonstrate the feasibility of this approach, we have recently created a synthetic 'chemical transducer'4 that enables platelet-derived growth factor (PDGF) to trigger the cleavage of an anticancer prodrug by activating glutathione-s-transferase (GST), which is not its natural binding partner. The structure of this 'transducer' consists of an anti-PDGF DNA aptamer that is modified with a bivalent inhibitor for GST. Hence, this synthetic agent belongs to a family of molecules with binding sites to different proteins,5-7 such as chemical inducers of dimerization (CIDs)8-10 and also to the group of protein-binders based on oligonucleotide-synthetic molecule conjugates.11-21
The general principles underlying the design of such systems is described herein and detailed protocols for synthesizing and testing the function of this 'transducer' with conventional enzymatic assays are provided. This work is intended to facilitate developing additional 'transducers' of this class, which may be used to mediate intracellular protein-protein communication and consequently, to induce artificial cell signaling pathways.
Figure 1 schematically describes the operating principles of synthetic 'chemical transducers' that can mediate unnatural protein-protein communications. In this illustration, a 'chemical transducer', which integrates synthetic binders for proteins I and II (binders I and II), enables protein II to trigger the catalytic activity of protein I, which is not its natural binding partner. In the absence of protein II, the transducer binds the catalytic site of the enzyme (protein I) and inhibits its activity (Figure 1, state ii). The binding of the 'transducer' to protein II, however, promotes interactions between binder I and the surface of protein II (Figure 1, state iii), which reduces its affinity toward protein I. As a result, the effective concentration of the 'free' transducer in the solution is reduced, which leads to dissociation of the transducer-protein I complex and to reactivation of protein I (Figure 1, state iv). Taken together, these steps highlight three fundamental principles underlying the design of efficient 'transducers': (1) a 'transducer' should have a specific binder for each of the protein targets, (2) the interaction between binder II and protein II should be stronger than the interaction between binder I and protein I, and (3) binder I must be able to interact with the surface of protein II. This last principle does not necessarily require that binder I alone would have a high affinity and selectivity toward protein II. Instead, it is based on our recent studies which showed that bringing a synthetic molecule in proximity to a protein is likely to promote interactions between this molecule and the surface of the protein.19,22,23
Figure 1: Operating principles of 'chemical transducers'. When the 'chemical transducer' is added to an active protein I (state i), it binds to its active site through binder I and inhibits its activity (state ii). In the presence of protein II, however, the unbound 'chemical transducer' interacts with protein II through binder II, which promotes interactions between binder I and the surface of protein II. This induced binder I-protein II interaction reduces the effective concentration of binder I, which leads to dissociation of the 'transducer'-protein I complex and to protein I reactivation (state iv). Please click here to view a larger version of this figure.
1. Synthesis of the 'Chemical Transducer'
2. Controlling GST Activity by PDGF
The design, synthesis, and mechanism of action of a 'chemical transducer' that can induce artificial communication between PDGF and GST are presented in Figure 2. The structure of the 'transducer' integrates a PDGF DNA aptamer and a bis-ethacrynic amide (bEA), which is a known GST inhibitor (Figure 2a).19 These binders enable the 'transducer' to bind both PDGF and GST with different affinities, namely, with dissociation ...
We presented a method for designing and testing of a 'chemical transducer' that can induce artificial communication between two naturally unrelated proteins, GST and PDGF, without modifying the native proteins. The unnatural GST-PDGF communications could be detected in real time by using enzymatic assays that follow the changes in the activity of GST in the presence of the 'chemical transducer' and increasing the concentrations of PDGF. In addition to detecting the activation of GST by PDGF, these assays were used to fol...
The authors have nothing to disclose.
This research was supported by the Minerva Foundation, the HFSP Organization, and a European Research Council Grant (Starting Grant 338265).
Name | Company | Catalog Number | Comments |
1-chloro-2,4-dinitrobenzene | Sigma-Aldrich | 237329 | |
Acetic acid | Bio Lab | 01070521 | |
Acetnitrile | J.T.Baker | 9017-03 | |
Ascorbic acid | Sigma-Aldrich | A4544 | |
Copper(II) Sulfate pentahydrate | Merck-Millipore | 102790 | |
Dimethyl sulfoxide | Merck-Millipore | 802912 | |
Dulbecco's Phosphate Buffered Saline | Biological Industries | 02-023-5A | |
Ethacrynic acid | Tokyo Chemical Industry Co. Ltd | E0526 | |
Glutathione-s-transferase M1-1 | Israel Structural Proteomics Center (Weizmann Institute of Science, Rehovot, Israel) | ||
JS-K | Sigma-Aldrich | J4137 | |
L-glutathione reduced | Sigma-Aldrich | G4251 | |
Magnesium Chloride | J.T.Baker | 0162 | |
nitrate/nitrite colorimetric assay kit | Cayman Chemical | 780001 | |
Oligonucleotides | W. M. Keck Foundation Biotechnology at Yale University | custom order | |
PDGF-BB | Israel Structural Proteomics Center (Weizmann Institute of Science, Rehovot, Israel) | ||
TBTA | Sigma-Aldrich | 678937 | |
Triethylamine | Sigma-Aldrich | T0886 | |
Desalting column | GE Healthcare | illustra MicroSpin G-25 Columns | |
HPLC | Waters | 2695 separation module | |
HPLC column | Waters | XBridgeTM OST C18 column (2.5 μM, 4.6 mm × 50 mm) | |
HPLC column | Waters | XBridgeTM OST C18 column (2.5 μM, 10 mm × 50 mm) | |
Plate reader | BioTek | synergy H4 hybrid |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved